.


:




:

































 

 

 

 





, . , , - .

"" "" (, ) . , 10 , 1 , "" 0,1. "" 0,05.

"" . , .1.1. : ( ) , .

1.1

" ",
1     100%
2     93%
3     89%
  : 153    

"" . - , ( ).

"" . , . .

, . , , , , , . , - , . .

" " - , , , .. , - " " . "" , , .

" " . , -. , , . : " ", " ", "", " " . .

" " , -. "" ( 0, 001).

" " " " ( " " " "). (, ), - .

" ", ( - "" ""), ( ). , . , "" , ( " ") . 1.2. , " " .

 

 

1.2

""

 
+  
 

" " - ( ) , , , () . , . , "" 1,0. , , "", "", "". "DIALOG", ( "Vinorelbine") ( ):

Title Vinorelbine.

Source Adis R&D Insight.

Synonyms Generic name: Vinorelbine Synonyms: KW 2307, KW 3407, NVB, Vinorelbine tartrate Brand names: Navelbine Chemical name: C'-norvincaleukoblastine, 3',4'-didehydro-4'-deoxy-.

CAS registry number 71486-22-1.

Related CAS registry no's 125317-39-7.

Molecular formula C45 H54 N4 O8.

Mechanism of action Tubulin antagonists.

Company name Originator: Pierre Fabre (France). Licensee(s):

Bender, Erkim, Gedeon Richter, Glaxo Wellcome, Glaxo Wellcome, Kyowa Hakko Kogyo, Rhodia, Rhone-Poulenc Rorer, Rhone-Poulenc Rorer, Rontag, Rontag, Rontag.

Parent company Pierre Fabre.

Other companies Pharmacia & Upjohn.

" ", , . , 6000000 , 600 . , "", , , 0,5-0,7. . : - . - EUROPAGES, , , . 1.3.

 

. 1.3.

 


 





:


: 2015-10-19; !; : 434 |


:

:

, , .
==> ...

1703 - | 1377 -


© 2015-2024 lektsii.org - -

: 0.011 .